---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-023741"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:11:05.905347+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports Q4 net loss of $1.40/share; Attruby launch with 1,028 scripts, EU approval triggers $75M milestone

## Summary
- Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.
- Q4 2024 net loss $265.1M ($1.40 EPS); full-year net loss $535.8M ($2.88 EPS).
- Q4 revenue $5.9M including $2.9M Attruby sales; full-year revenue $221.9M driven by $207.7M from Bayer/Kyowa Kirin deals.
- Cash, cash equivalents and short-term restricted cash $681.2M at Dec 31, 2024, up from $392.6M at Dec 31, 2023.
- Three Phase 3 trials (LGMD2I, ADH1, achondroplasia) fully enrolled; last participant last visit expected 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-023741
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/0000950170-25-023741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/bbio-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-023741
- JSON: https://secwatch.observer/filing/0000950170-25-023741.json
- Plain text: https://secwatch.observer/filing/0000950170-25-023741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.